These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26432076)

  • 1. Combination therapy for multidrug-resistant cytomegalovirus disease.
    Stuehler C; Stüssi G; Halter J; Nowakowska J; Schibli A; Battegay M; Dirks J; Passweg J; Heim D; Rovo A; Kalberer C; Bucher C; Weisser M; Dumoulin A; Hirsch HH; Khanna N
    Transpl Infect Dis; 2015 Oct; 17(5):751-5. PubMed ID: 26432076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide.
    Ehlert K; Groll AH; Kuehn J; Vormoor J
    Klin Padiatr; 2006; 218(3):180-4. PubMed ID: 16688677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature.
    Verkaik NJ; Hoek RA; van Bergeijk H; van Hal PT; Schipper ME; Pas SD; Beersma MF; Boucher CA; Jedema I; Falkenburg F; Hoogsteden HC; van den Blink B; Murk JL
    Transpl Infect Dis; 2013 Dec; 15(6):E243-9. PubMed ID: 24298985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent CMV infection after allogeneic hematopoietic stem cell transplantation in a CMV-seronegative donor-to-positive recipient constellation: Development of multidrug resistance in the absence of anti-viral cellular immunity.
    Herling M; Schröder L; Awerkiew S; Chakupurakal G; Holtick U; Kaiser R; Pfister H; Scheid C; Di Cristanziano V
    J Clin Virol; 2016 Jan; 74():57-60. PubMed ID: 26672492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy.
    Hakki M
    Curr Hematol Malig Rep; 2020 Apr; 15(2):90-102. PubMed ID: 31981100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation.
    Battiwalla M; Paplham P; Almyroudis NG; McCarthy A; Abdelhalim A; Elefante A; Smith P; Becker J; McCarthy PL; Segal BH
    Transpl Infect Dis; 2007 Mar; 9(1):28-32. PubMed ID: 17313468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation.
    Maffini E; Giaccone L; Festuccia M; Brunello L; Busca A; Bruno B
    Expert Rev Hematol; 2016 Jun; 9(6):585-96. PubMed ID: 27043241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report.
    Ciszek M; Mucha K; Foroncewicz B; Chmura A; Pączek L
    Ann Transplant; 2014 Jan; 19():60-3. PubMed ID: 24481271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Developments in the Management of Cytomegalovirus Infection After Transplantation.
    Meesing A; Razonable RR
    Drugs; 2018 Jul; 78(11):1085-1103. PubMed ID: 29961185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients.
    El Chaer F; Shah DP; Chemaly RF
    Blood; 2016 Dec; 128(23):2624-2636. PubMed ID: 27760756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
    Rodriguez J; Casper K; Smallwood G; Stieber A; Fasola C; Lehneman J; Heffron T
    Liver Transpl; 2007 Oct; 13(10):1396-400. PubMed ID: 17902124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor CMV-specific cytotoxic T lymphocytes successfully treated drug-resistant cytomegalovirus encephalitis after allogeneic hematopoietic stem cell transplantation.
    Ke P; Bao X; Zhou J; Li X; Zhuang J; He X; Wu D; Zhang X; Ma X
    Hematology; 2020 Dec; 25(1):43-47. PubMed ID: 31906810
    [No Abstract]   [Full Text] [Related]  

  • 13. Ganciclovir and foscarnet dual-therapy for cytomegalovirus encephalitis: A case report and review of the literature.
    Baghban A; Malinis M
    J Neurol Sci; 2018 May; 388():28-36. PubMed ID: 29627026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series.
    El Chaer F; Mori N; Shah D; Oliver N; Wang E; Jan A; Doan V; Tverdek F; Tayar J; Ariza-Heredia E; Chemaly RF
    Antiviral Res; 2016 Nov; 135():91-96. PubMed ID: 27594527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CMV-specific immune reconstitution following allogeneic stem cell transplantation.
    Blyth E; Withers B; Clancy L; Gottlieb D
    Virulence; 2016 Nov; 7(8):967-980. PubMed ID: 27580355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus.
    Germi R; Mariette C; Alain S; Lupo J; Thiebaut A; Brion JP; Epaulard O; Saint Raymond C; Malvezzi P; Morand P
    Antiviral Res; 2014 Jan; 101():57-61. PubMed ID: 24184983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.
    Peggs KS; Verfuerth S; Pizzey A; Khan N; Guiver M; Moss PA; Mackinnon S
    Lancet; 2003 Oct; 362(9393):1375-7. PubMed ID: 14585640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
    Hazar V; Kansoy S; Küpesiz A; Aksoylar S; Kantar M; Yeşilipek A
    Bone Marrow Transplant; 2004 May; 33(9):931-5. PubMed ID: 15034541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
    Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
    J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.